P ROBLEMS WITH N EW P SYCHOACTIVE S UBSTANCES AND HOW TO DEAL WITH IT Roman Gabrhelík Serbia, 2013.

Slides:



Advertisements
Similar presentations
Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November 2010.
Advertisements

2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Online Sales and Use of Synthetic Cannabinoids Preliminary findings from a Norwegian study Ola Røed Bilgrei Anne Line Bretteville-Jensen SIRUS.
Overview of the 2010 work programme Paul Griffiths, Roland Simon, Rosemary de Sousa Scientific Committee meeting, Lisbon, November 2009.
European Early Warning System Charlotte Davies. European Early Warning System Adopted in May 2005, the Council Decision 2005/387/JHA on the information.
Understanding the management of risks to health and safety on the premises of a retail business Unit 352.
Strenghtening collaboration with Serbia - IPA4 Project expected outcomes Frédéric Denecker, Programme Management Officer Reitox and International Cooperation.
Prevention of problem gambling March 27th, Lethbridge The evidence for prevention: Lessons from the substance abuse field.
Presentation Package for Concepts of Fitness and Wellness 6e Section VII: Concept 22 Use and Abuse of Other Drugs.
Medicines and Drugs Chapter 23.
Addiction UNIT 4: PSYA4 Content The Psychology of Addictive Behaviour Models of Addictive Behaviour  Biological, cognitive and.
History 2010 Law enforcement first started hearing about “Synthetic cocaine” Not actually cocaine, but Mephedrone At that time, very little was known Illegal.
ESPAD – are young Europeans getting more alike? Björn Hibell EMCDDA Conference Identifying Europe's Information needs for effective drug.
LEGAL AND ILLEGAL SUBSTANCES. LEGAL DRUGS Legal drugs are considered permissible for use, and are either prescribed by a physician (prescription medications)
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Tim Pfeiffer-Gerschel, DBDD Dubrovnik, Jan 2008CARDS EWS CARDS 2004, Component 4 Early Warning System Tim Pfeiffer-Gerschel National Focal Point.
1.6 focuses on the following drug related issues: 1.Personal, interpersonal and societal influences on an individuals drug use. 2.The effect of drugs on.
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
Trends and developments Selected trends and some insights in prevention Vilnius, 12 November 2014 Roland Simon.
Annual report 2009: the state of the drugs problem in Europe NB Embargo 5 November :00 CET (Brussels time)
An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.
A look into the Expert Panels Review By Leigh
Novel Psychoactive Substances- Not for Human Consumption 2014 Dr Duncan WA Stewart Consultant Addictions Psychiatrist.
Revision of Problem Drug Use indicator Danica Klempová and Julián Vicente 42nd Reitox HFP meeting, 27 May 2010.
Ecstasy and Herbal Ecstasy This Lesson Plan Produced By Your Drug Demand Reduction Program 1.
Paul Griffiths and Roland Simon Wrap-up presentation What has the EMCDDA learned ?
ELDD Reflection – past, present and future 29th Meeting of the Scientific Committee, 18 Nov 2008.
What are the top 10 drugs mis-used by young people?
Youth In Focus!! Maria Peglitsi Cyprus Anti Drug Council July 2009.
Designer and look-alike drugs
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research The majority of synthetic.
LOCAL PASS A Local approach towards the reduction of PsychoActive Substance uSe Renée Otte February 5, 2015.
Designer and look-alike drugs
Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.
Citywide Drugs Crisis Campaign 20 years experience of Community Involvement – Key Lessons for the next National Drugs Strategy 12 TH NOVEMBER 2015.
1 Psychology 320: Psychology of Gender and Sex Differences Lecture 54.
TEDI TEDI Trans European Drug Information Mireia Ventura – Energy control Barcelona Alexander Bücheli – City of Zurich youth counseling Streetwork.
PRESCRIPTION DRUG ABUSE Part 2. LEARNING GOALS  I will be able to identify the pitfalls of prescription drug use.  I will be able to use the information.
Launch of the INCB Annual Reports March 2016.
NEW PSYCHOACTIVE SUBSTANCES ROMANIA’s Experience Lavinius Sava– sociologist NAA/ Romania’sFocal Point Budapest,
NPS and Importance of Information Sharing Dr Richard Stevenson A&E Department, Glasgow Royal Infirmary Dr Hazel Torrance Forensic Medicine and Science.
Annual report 2012: the state of the drugs problem in Europe Name, date.
Collaboration between the national EWS and treatment service providers in Hungary Anna Péterfi Hungarian National Focal Point TAIEX seminar Zagreb,
Overview of the cannabis use in Europe Paul Griffiths, Reitox academy, Berlin, 29th March 2007.
ESPAD Report 2015 Results from the European School Survey Project on Alcohol and Other Drugs ESPAD Group Lisbon, 20 September 2016.
What are Drugs?.
PMMA (paramethoxymethamphetamine) in “legal highs” in Spain
NPN Workshop Overview and Implications for Prevention
Novel Psychoactive Substances- Not for Human Consumption 2014
THE GERMAN NEW PSYCHOACTIVE SUBSTANCE LAW (NPSG): PERCEIVED AND EXPECTED OUTCOMES IN THE FIRST STAGE OF IMPLEMENTATION. Tessa-Virginia Hannemann.
Crime and the Law Drugs, the Law and Government Responses.
The social epidemiology of alcohol and drug use among Israeli school-aged children: Recent developments and current challenges Prof. Yossi Harel-Fisch.
New Psychoactive Substances (NPS) in Deep Web Marketplaces (DWM):
Results of an international drug testing service for cryptomarket users Mireia Ventura· ABD – Energy Control 15th May 2017.
Social Awareness Programme
What are Drugs?.
Comparison of data from WBE with other sources
A Spanish Drug Checking service for recreational drug users
Second European Conference on Addictive Behaviours and Dependencies
New Psychoactive Substances in Portugal
Legalization of Drugs The Dutch experience.
Designer drugs of abuse: The science behind the headlines
Drugs the law & government responses
Novel Psychoactive Substances- Not for Human Consumption 2014
Skopje, 21 November 2017, General Population Survey results– launch
Risk Reduction on New Drugs,
TEDI project (Trans European Drug Information)
Presentation transcript:

P ROBLEMS WITH N EW P SYCHOACTIVE S UBSTANCES AND HOW TO DEAL WITH IT Roman Gabrhelík Serbia, 2013

NSPs - terminology New psychoactive substance (NPS) that is not controlled by intnt’l UN treaties dating 1961 a 1971, may have equal impact on public health as already controlled substances (Council Decision 2005/387/JHA) = ‘designer drugs’, ‘ethno botanicals’, ‘research chemicals’… = „legal highs“ X but not so „legal“ = Synthetic substances („new synthetic drugs“ - NSD) Cannabinoids of herbal origin May come in different forms: herbal mixtures, powders, crystals, tablets, solutions…

Actual Trend Prohibition creates incentives for the production of other substances Every year there are more new substances than in the previous year Every new substance we know less than the previous one (=risk unknown) Made illegal in EU NSs Total NPSs

What are the NSPs?

Dependence A dependence on these substances is highly questionable, given the the two following reasons: We don’t have enough scientifically reliable data The sporadic use does not allow us to monitor development of addiction. However, given the experience with similar substances, particularly MDMA and some hallucinogens, we assume that some of these substances may have the potential to cause psychological dependence. The physical addiction is no information available (Palenicek).

‘Don’t knows’ related with NPS 1. How many NPS users there are? 2. How to ask correctly for prevalence? different products, materials different understanding difficult to describe 3. What are the main sources of NPS supply the drug market? Online shops vs. under-the-counter New methods of selling – via a mediator 4. What new substances are actually used? What is being sold Is what is being sold actually used 5. What are the risks of NPS? EWS x new undetectable substances Discussion forum

1. Prevalence - Who to ask? What is the prevalence of use of NPS (comp. to ‘traditional’ drugs)? General population Population studies Online surveys School populations (e-)shops have no age limits Night life venues / Music events Experimentators Party goers Recreational drug users / Experimentators Availability / price

2. Prevalence - How to ask? Questions asking about use in the lifetime, the past 12 months, past 30 days separately for each type of substance Synthetic cannabinoids New synthetic drugs Herbal drugs What substance Do you know the structural formula of the substance used? (MDPV, MCPP..) If not, do you know the chemical group? (piperazines, tryptamines) How the drug was called? Funky / Plan B / Euphoria (and others) If not, what was the effect of the drug? (stimulant, hallucinogen, downer)

2. So what is the prevalence Relatively low compared with ‘traditional’ illicit substances for the general and school student populations. General population; LifetimePrev (EMQ): Highest: Ireland (2011) (15-64 years) 3.5%; (15-34 years) 6.7% School population; (EMQ): Croatia (2011) 7.5% any NSP; Latvia (2011) (15-16 years) 11% Spice NPS using popul.; Czech (N=151; aged 15-34) (Mravčík, 2012): 80% used in the past year, 7% in the past month 1/3 used mephedron or other catinone 10-15% used synthetic cannabinoids Past year Regular use 2%, Repeated use 51%, Once 47% Obtaining from Friends 74%, the rest from shops and online shops

3. What main sources of NPS supply the drug market? Until around 10 years ago, most NPS appearing on the European drug scene were produced in underground laboratories or sourced from diverted medicines and sold directly on the illicit drug market. Today, NPS are produced in China and India, imported to Europe in bulk, than processed, packaged, and sold as 'legal highs'. Sometimes sold on the streets as substitutes for meth/amphetamine, ecstasy, heroin or cocaine (EMCDDA website). Recently, ‘legal highs’ business moved to → 2010 / 2011 Amsterdam shops → 2012 / 2013 internet, under-the-counter

3. How to monitor the drug market? Mistery shopping Physical monitoring of the shop Talking to sellers and customers Web scraping - indexing information from the web using technology similar to that used by standard search engines From the unstructured content (XY stores and products on the web for different prices → updated database of shops and substances) Using ‘compare prices’ approach and other marketing tools How does it work: 1. Keywords defining shops - web search 2. Coding of the most visited sites → product database marketing strategy and market behavior response to law enforcement

4. What new substances are actually used? Substances obtained and tested from: Online shops Dance scene Experimenting users Problem drug users Testing of: the actual drug drug in the body New drugs = unknown metabolites = hard to identify the drug In Czech, in cooperation with the Institute of Criminology and Water Management Research Institute - transfer "laundered samples"

4. Early Warning System (EMCDDA) The EWS provides EU Member States with an information exchange mechanism for reporting on the emergence of new psychoactive substances. It is a key element in the European fast-track system for assessing and responding to new drugs. In 2012, the list of substances reported was dominated by 30 synthetic cannabinoids, which mimic the effects of cannabis. Risk assessments of two very different substances in 2012 which were linked to over 40 deaths in Europe. The first, 4-MA (a stimulant) was being sold as amphetamine on the illicit market, while the second, 5-IT (reported to have both stimulant and hallucinogenic effects) In March 2013, the Council of the EU decided to subject 4-MA to controls across the EU.

5. What are the risks of NPS? Information from EWS We (users themselves) do not know what is being actually used. Therefore, to assess the effects of the drugs is difficult. Even sellers do not inform / know the risks What was done is: Analyses of Discussion forums on the internet (e.g. Erowid) Qualitative research (with individuals identified via internet) How NSD user reduces risk: at first enjoys the smaller amounts of the drug effort not to combine with other substances searching for information on the substance

Drug policy implications Since 04/2011: 33 new illegal drugs & Amsterdam shop owner put in jail for promoting drug use proposal to amend Act No. 167/1998: New drugs banned by the Government Order, but not as Law Attachments = acceleration process Germany classifies suspicious substance on a temporary list, from which it passes to a permanent ban only if a substance proves as hazardous within a year introduce risk-assesment to the Czech legislation, so the costs of the ban do not outweigh its benefits

Implications for prevention Clear message: 'Legal‘ not meaning without risk and possible harm Step 1 Educate the providers Produce education and prevention materials Step 2 Include NPS in prevention education The messages must be age sensitive Provide information - Raise awareness but be aware of risk of being instructive! Boys seem to be more vulnerable than girls (gender sensitive info) Improve Refusal skills

To conclude There is a lot of unknown. However, this should not stop us from doing anything. A lot can be done if we take quick and efficient actions on the policy, prevention and treatment levels.

Thank you for your attention